Table 1.

Anti IgE treatment in severe asthma and clinical outcomes

Study	No. of patients	No. of patients treated with anti-IgE	Outcome
Bousquet et al. (24)	4,308	2,511	⇓Exacerbation 38% ⇓Hospital admissions 52% ⇓ER visits 47%
Humbert et al. (25)	419	419	⇓Exacerbation rate 26% ⇑ QoL ⇑ Morning PEF ⇓Symptom scores
Normansell et al. (26)			⇓Exacerbation ⇓Hospitalisation ⇓ICS daily dose
Abraham et al. (27)			⇓Exacerbation ⇓Hospitalisations ⇓ER visits ⇓OCS 30–66%
Busse et al. (28)	419	208	⇓Number of days with asthma symptoms 24.5% ⇓Exacerbations ⇑ Asthma control: omalizumab+lower doses of inhaled glucocorticoids (p <0.001) and LABA (p=0.003)
Hanania et al. (29)	850	427	⇓Mean daily albuterol puffs ⇓(−0.27 puff/day) ⇓Exacerbations ⇑ AQLQ(S) scores ⇓Asthma symptom score
Chen. et al. (30)			⇓Total ICS dose ⇓SABA ⇓LTRA

ER, emergency room; PEF, peak expiratory flow; ICS, inhaled corticosteroids; LABA, long acting beta2 agonists; AQLQ, Asthma Quality of Life Questionnaire; SABA, short acting beta2 agonists; LTRA, leukotriene receptor antagonists.